2020 KSMI专家共识:急性心肌梗死的药物治疗

2020-09-20 国外心血管相关专家小组(统称) Korean Circ J . 2020 Oct;50(10):845-866.

2020年9月,韩国心肌梗死学会(KSMI)发布了急性心肌梗死的药物治疗专家共识,本文主要针对急性心肌梗死的药物治疗的相关内容提供专家共识指导。

中文标题:

2020 KSMI专家共识:急性心肌梗死的药物治疗

英文标题:

2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction

发布日期:

2020-09-20

简要介绍:

2020年9月,韩国心肌梗死学会(KSMI)发布了急性心肌梗死的药物治疗专家共识,本文主要针对急性心肌梗死的药物治疗的相关内容提供专家共识指导。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 KSMI专家共识:急性心肌梗死的药物治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=79b2a1c001991137, title=2020 KSMI专家共识:急性心肌梗死的药物治疗, enTitle=2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction, guiderFrom=Korean Circ J . 2020 Oct;50(10):845-866., authorId=0, author=, summary=2020年9月,韩国心肌梗死学会(KSMI)发布了急性心肌梗死的药物治疗专家共识,本文主要针对急性心肌梗死的药物治疗的相关内容提供专家共识指导。, cover=https://img.medsci.cn/20201016/1602856821143_2020535.jpg, journalId=0, articlesId=null, associationId=738, associationName=国外心血管相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Sun Sep 20 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年9月,韩国心肌梗死学会(KSMI)发布了急性心肌梗死的药物治疗专家共识,本文主要针对急性心肌梗死的药物治疗的相关内容提供专家共识指导。</p> </div> </div> </div>, tagList=[TagDto(tagId=678, tagName=急性心肌梗死)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=43, categoryName=冠心病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=678, guiderKeyword=急性心肌梗死, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6246, appHits=652, showAppHits=0, pcHits=1489, showPcHits=5589, likes=2, shares=34, comments=11, approvalStatus=1, publishedTime=Fri Oct 16 22:16:31 CST 2020, publishedTimeString=2020-09-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Fri Oct 16 22:00:28 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 22:33:35 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 KSMI专家共识:急性心肌梗死的药物治疗.pdf)])
2020 KSMI专家共识:急性心肌梗死的药物治疗.pdf
下载请点击:
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=974412, encodeId=7c6a9e44120a, content=非常好的资源, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/H3QXYibjbzM9C5GELMGhjqMatvmOsXy5gzoqIT6XJqYYCg7BqyfaLVW7gmk0bjAUJygFZUxt3XakaHUP7VIGDww/132, createdBy=a1285314326, createdName=taken110, createdTime=Thu Jun 17 15:21:38 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966254, encodeId=4fd6966254e6, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>你你你你, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d285128883, createdName=14650232m09暂无昵称, createdTime=Mon May 17 13:48:35 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904875, encodeId=80729048e521, content=药物治疗有限,介入治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a5441392, createdName=二燕, createdTime=Fri Dec 04 15:36:16 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902815, encodeId=6e02902815c3, content=学习进步, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/13/9e868433697f9337bc9c6b44718fa935.jpg, createdBy=e0062060044, createdName=公冶花, createdTime=Fri Nov 27 15:01:48 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895694, encodeId=3e93895694d1, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51c75410635, createdName=ms2000001591761073, createdTime=Fri Oct 30 17:43:29 CST 2020, time=2020-10-30, status=1, ipAttribution=)]
    2021-06-17 taken110

    非常好的资源

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=974412, encodeId=7c6a9e44120a, content=非常好的资源, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/H3QXYibjbzM9C5GELMGhjqMatvmOsXy5gzoqIT6XJqYYCg7BqyfaLVW7gmk0bjAUJygFZUxt3XakaHUP7VIGDww/132, createdBy=a1285314326, createdName=taken110, createdTime=Thu Jun 17 15:21:38 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966254, encodeId=4fd6966254e6, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>你你你你, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d285128883, createdName=14650232m09暂无昵称, createdTime=Mon May 17 13:48:35 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904875, encodeId=80729048e521, content=药物治疗有限,介入治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a5441392, createdName=二燕, createdTime=Fri Dec 04 15:36:16 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902815, encodeId=6e02902815c3, content=学习进步, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/13/9e868433697f9337bc9c6b44718fa935.jpg, createdBy=e0062060044, createdName=公冶花, createdTime=Fri Nov 27 15:01:48 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895694, encodeId=3e93895694d1, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51c75410635, createdName=ms2000001591761073, createdTime=Fri Oct 30 17:43:29 CST 2020, time=2020-10-30, status=1, ipAttribution=)]
    2021-05-17 14650232m09暂无昵称

    #学习#你你你你

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=974412, encodeId=7c6a9e44120a, content=非常好的资源, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/H3QXYibjbzM9C5GELMGhjqMatvmOsXy5gzoqIT6XJqYYCg7BqyfaLVW7gmk0bjAUJygFZUxt3XakaHUP7VIGDww/132, createdBy=a1285314326, createdName=taken110, createdTime=Thu Jun 17 15:21:38 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966254, encodeId=4fd6966254e6, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>你你你你, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d285128883, createdName=14650232m09暂无昵称, createdTime=Mon May 17 13:48:35 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904875, encodeId=80729048e521, content=药物治疗有限,介入治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a5441392, createdName=二燕, createdTime=Fri Dec 04 15:36:16 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902815, encodeId=6e02902815c3, content=学习进步, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/13/9e868433697f9337bc9c6b44718fa935.jpg, createdBy=e0062060044, createdName=公冶花, createdTime=Fri Nov 27 15:01:48 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895694, encodeId=3e93895694d1, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51c75410635, createdName=ms2000001591761073, createdTime=Fri Oct 30 17:43:29 CST 2020, time=2020-10-30, status=1, ipAttribution=)]
    2020-12-04 二燕

    药物治疗有限,介入治疗

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=974412, encodeId=7c6a9e44120a, content=非常好的资源, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/H3QXYibjbzM9C5GELMGhjqMatvmOsXy5gzoqIT6XJqYYCg7BqyfaLVW7gmk0bjAUJygFZUxt3XakaHUP7VIGDww/132, createdBy=a1285314326, createdName=taken110, createdTime=Thu Jun 17 15:21:38 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966254, encodeId=4fd6966254e6, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>你你你你, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d285128883, createdName=14650232m09暂无昵称, createdTime=Mon May 17 13:48:35 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904875, encodeId=80729048e521, content=药物治疗有限,介入治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a5441392, createdName=二燕, createdTime=Fri Dec 04 15:36:16 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902815, encodeId=6e02902815c3, content=学习进步, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/13/9e868433697f9337bc9c6b44718fa935.jpg, createdBy=e0062060044, createdName=公冶花, createdTime=Fri Nov 27 15:01:48 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895694, encodeId=3e93895694d1, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51c75410635, createdName=ms2000001591761073, createdTime=Fri Oct 30 17:43:29 CST 2020, time=2020-10-30, status=1, ipAttribution=)]
    2020-11-27 公冶花

    学习进步

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=974412, encodeId=7c6a9e44120a, content=非常好的资源, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/H3QXYibjbzM9C5GELMGhjqMatvmOsXy5gzoqIT6XJqYYCg7BqyfaLVW7gmk0bjAUJygFZUxt3XakaHUP7VIGDww/132, createdBy=a1285314326, createdName=taken110, createdTime=Thu Jun 17 15:21:38 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966254, encodeId=4fd6966254e6, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>你你你你, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d285128883, createdName=14650232m09暂无昵称, createdTime=Mon May 17 13:48:35 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904875, encodeId=80729048e521, content=药物治疗有限,介入治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c02a5441392, createdName=二燕, createdTime=Fri Dec 04 15:36:16 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902815, encodeId=6e02902815c3, content=学习进步, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/13/9e868433697f9337bc9c6b44718fa935.jpg, createdBy=e0062060044, createdName=公冶花, createdTime=Fri Nov 27 15:01:48 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895694, encodeId=3e93895694d1, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51c75410635, createdName=ms2000001591761073, createdTime=Fri Oct 30 17:43:29 CST 2020, time=2020-10-30, status=1, ipAttribution=)]
    2020-10-30 ms2000001591761073

    学习了

    0